Results 111 to 120 of about 26,086 (200)

Targeting TIGIT for cancer immunotherapy: recent advances and future directions

Biomarker Research
As a newly identified checkpoint, T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is highly expressed on CD4+ T cells, CD8+ T cells, natural killer (NK) cells, regulatory T cells (Tregs), and tumor ...
Peng Zhang, Xinyuan Liu, Zhuoyu Gu, Zhongxing Jiang, Song Zhao, Yongping Song, Jifeng Yu   +6 more
doaj   +1 more source

Periodontal Medicine Rewired: Mechanisms Linking Periodontitis to Systemic Diseases

Journal of Periodontal Research, EarlyView.
This review reorganizes decades of research in periodontal medicine into a multi‐dimensional framework, illustrating how periodontitis influences systemic health through at least seven interconnected mechanisms. ABSTRACT Periodontitis is now recognized not merely as a localized oral condition but as a systemic disease linked to over 70 communicable and
Mario Romandini, George Hajishengallis, Mike Curtis, Giacomo Baima   +3 more
wiley   +1 more source

The Oral‐Gut Axis: Bidirectional Interactions Between Microbiome and Diseases

Journal of Periodontal Research, EarlyView.
This study aims to summarize the mechanisms underlying ectopic colonization of the gut by oral pathobionts and the microbial and host factors that regulate this process. ABSTRACT Increased colonization of typically oral microorganisms is frequently observed in the gut mucosa or lumen of individuals with gastrointestinal disorders, including patients ...
Shinya Ebihara, Nobuhiko Kamada
wiley   +1 more source

The Dual Face of Fusobacterium nucleatum in Cancer: Foe, Friend or Both?

Journal of Periodontal Research, EarlyView.
Fusobacterium nucleatum has established interactions with cancers in humans. However, contrary to a traditional view that these interactions are uniformly pro‐tumoural, recent evidence suggests a more nuanced role, where contact‐dependent and contact‐independent mechanisms may support either tumour progression or restriction depending on tumour site ...
Anjali Chander, Huile Lim, Gilad Bachrach, Miguel Reis Ferreira   +3 more
wiley   +1 more source

Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy [PDF]

Tiragolumab, a monoclonal antibody (mAb) targeting T cell immunoreceptor with Ig and ITIM domains (TIGIT), represents a novel approach in cancer immunotherapy.
Kosar Ghasemi
core   +1 more source

TIGIT agonism as a therapeutic strategy to suppress inflammation in hidradenitis suppurativa

Frontiers in Immunology
Hidradenitis suppurativa (HS) is a chronic, heterogeneous inflammatory skin disorder with limited therapeutic options. The immune checkpoint receptor TIGIT is emerging as a regulator of chronic inflammation, yet its role in HS remains unknown.
Michal Kidacki, Anjali Jaiswal, Christina Cho, Samantha Prince, Rachel Breidbart, Henry Hsia, Matthew D. Vesely, Lieping Chen, Lieping Chen   +8 more
doaj   +1 more source

Translating gut microbiome research into therapies for type 1 diabetes

Experimental Physiology, EarlyView.
Abstract Type 1 diabetes (T1D) is characterised by the loss of functional pancreatic β‐cells, for which lifelong insulin therapy remains the standard of care. Given that the gut microbiome can influence host health and that shifts in gut microbial profiles have been observed in T1D, growing interest has emerged in the role of the gut microbiome in T1D,
Shanti P. Kok, Max Nieuwdorp, Elena Rampanelli   +2 more
wiley   +1 more source

Co-expression of PD-1, TIGIT and LAG-3 identifies HIV-infected cells during ART.

, 2016
(A) Pie chart representing the frequencies of memory CD4+ T cells co-expressing PD-1 and/or TIGIT and/or LAG-3 in cohort 1 (n = 48). Coloured bars on the right side designate categories of ICs expressing cells: Triple -: PD-1/TIGIT/LAG-3 triple—in blue ...
Gabriela Khoury (663684), Rafick-Pierre Sékaly (118474), Rebecca Hoh (283494), Elizabeth Sinclair (10445), Peter Bacchetti (75155), Lorrie Epling (374736), Frederick M. Hecht (68366), Sandrina DaFonseca (340405), Sharon R. Lewin (130160), Wendy Hartogensis (285034), Steven G. Deeks (131630), Mariam B. Lawani (2879693), Nicolas Chomont (175516), Rémi Fromentin (659658), Wendy Bakeman (2879696), Marisela Killian (2879690)   +15 more
core   +1 more source

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI‐SAFRADJU‐2501)

International Journal of Cancer, Volume 159, Issue 11, Page 2766-2777, 1 December 2026.
ABSTRACT The recommended adjuvant chemotherapy (adj‐ChT) regimen for resected biliary tract cancers (BTC) is capecitabine (Cape); yet, the recommendation is based on limited evidence. Although varied adj‐ChTs have been employed in practice, robust real‐world data is scarce. We conducted a national, multicenter, hospital‐based registry study to evaluate
Erman Akkus, Mehmet Kayaalp, Müzeyyen Aslı Ergözoğlu, Ilgın Koç Kuş, Doğan Bayram, Bilgeşah Kılıçtaş, Emel Ayvaz Güneyin, Ali Kalem, Haydar Temizyürek, Mehmet Mutlu Çatlı, Mehmet Sinan Akarca, Maral Martin Mıldanoğlu, Görkem Turhan, Mahmut Kara, Hacı Arak, Feyza Arslan Tan, Burak Paçacı, Berkay Yeşilyurt, Orhun Akdoğan, Emine Bihter Çetin, Selahattin Çelik, Fatma Keskin Uzundere, Elif Şahin, Zehra Sadak Öcal, Lamia Şeker Can, Bahadır Köylü, Mehmet Cem Fidan, Esmanur Kaplan Tüzün, Teoman Şakalar, Elif Sertesen Çamöz, Haydar Çağatay Yüksel, Onur Yazdan Balçık, Pınar Peker, Mehmet Yılmaz, Şeymanur Ala Enli, Erdem Kölemen, Sibel Oyucu Orhan, Yakup Düzköprü, Mustafa Ersoy, Tuğba Akın Telli, Mesut Yılmaz, Yusuf İlhan, Atila Yıldırım, Ramazan Coşar, Müslih Ürün, Arif Hakan Önder, Murat Araz, Ertuğrul Bayram, Havva Yeşil Çınkır, Ali Alkan, Mustafa Gürbüz, Nilüfer Avcı, Fatma Paksoy Türköz, İsmail Oğuz Kara, Fatih Köse, İlkay Tuğba Ünek, Ahmet Bilici, Öznur Bal, Şuayib Yalçın, Lorenza Rimassa, Hatime Arzu Yaşar   +60 more
wiley   +1 more source

TIGIT immune checkpoint blockade restores CD8 T cell immunity against multiple myeloma

, 2018
Immune-based therapies hold promise for the treatment of multiple myeloma (MM), but so far immune checkpoint blockade targeting programmed cell death protein 1 (PD-1) has not proven effective as single agent in this disease.
Harjunpää, Heidi, Kassem, Sahar, Teng, Michele, Avet-Loiseau, Hervé, Teng, Michele W. L., Smyth, Mark, Stannard, Kimberley, Miles, Kim, Weulersse, Marianne, Dougall, William C., Carrié, Nadège, Krumeich, Sophie, Nakamura, Kyohei, Hill, Geoffrey, Cuisinier, Marine, Guillerey, Camille, Smyth, Mark J., Teo, Tricia, Martinet, Ludovic, Minnie, Simone A., Yu, Yuan, Hill, Geoffrey R., Dougall, William, Minnie, Simone   +23 more
core   +1 more source